NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the area needed. The company announced 3Q results and continues to make tremendous progress in groundbreaking research surrounding the central nervous system and improved drug delivery through exosomes.
